TriLink BioTechnologies and Johns Hopkins University Establish RNA Innovation Center to Propel Transformational Research and Therapeutic Development
SAN DIEGO - TriLink BioTechnologies (TriLink), a leading global provider of life science reagents and services under Maravai LifeSciences (NASDAQ: MRVI), has joined forces with Johns Hopkins University to form a groundbreaking RNA Innovation Center aimed at expediting research in RNA therapeutics and discovery. The newly established center, housed within the Johns Hopkins Whiting School of Engineering, will leverage TriLink’s cutting-edge RNA synthesis technology to drive research and the development of innovative therapeutics. TriLink’s substantial investment in this collaboration signifies its dedication to advancing the field of RNA-based treatments.
TriLink BioTechnologies has recently announced the grand opening of a state-of-the-art mRNA cGMP manufacturing facility in San Diego. Covering an expansive 32,000 square feet, this purpose-built facility is designed to support drug developers in late-stage clinical trials and commercialization. Esteemed for adhering to cGMP guidelines, the facility will facilitate the production of advanced mRNA therapeutics and bolster the capabilities of pharmaceutical companies operating in this field.
The simultaneous unveiling of the RNA Innovation Center and the advanced mRNA manufacturing facility in San Diego marks TriLink BioTechnologies’ commitment to pioneering breakthroughs in the field of RNA-based therapeutics. By establishing this partnership with Johns Hopkins University, TriLink aims to create a collaborative ecosystem that drives transformative scientific exploration and accelerates the translation of cutting-edge research into life-changing therapies.
The newly formed center at Johns Hopkins Whiting School of Engineering holds immense potential to revolutionize the way we understand and treat diseases. With TriLink’s unparalleled expertise in RNA synthesis technology and Johns Hopkins University’s reputation as a global leader in biomedical research, this partnership is poised to MRVI Together, the two institutions will accelerate scientific discovery, fuel innovation, and ultimately improve the lives of patients worldwide.
Comments